A research study centered on magic mushrooms in Canada revealed that approximately 80% of participants believe that psilocybin, the active ingredient in magic mushrooms, should be medically available for patients in distress. Moreover, about two-thirds of the Canadian participants in the study concurred that psilocybin ought to be legally obtainable for those who require it.
Beyond advocating for wider availability, an impressive 84.8 percent of participants hold the view that the public health system should bear the expense of such treatments. A majority of Canadians regard psilocybin as a legitimate treatment alternative, especially for managing end-of-life distress.
[toc]
Key Findings:
- Citizens from Québec, Ontario, Alberta, and British Columbia regard psilocybin as a valid medical option for addressing end-of-life existential distress.
- Magic mushrooms are perceived as a safe treatment option for existential distress.
- Participants in two double-blind trials reported immediate and lasting benefits, with effects persisting for six months or even longer.
Understanding Existential Distress
Existential distress, akin to existential suffering, spiritual distress, and demoralization, arises when individuals grapple with their mortality. Patients may grapple with feelings of helplessness, isolation, anxiety, and a sense of losing meaning and purpose. This form of distress particularly impacts patients diagnosed with life-threatening diseases, potentially leading them to contemplate hastening death or suicide.
Generally, people facing terminal illnesses or major life changes are the ones who frequently experience this kind of distress. It profoundly impacts their mental health and overall life quality.
Existential therapy aims to tackle issues such as anxiety, depression, grief, loneliness, apathy, despair, identity confusion, and feelings of purposelessness and existential fear. This therapy may require multiple sessions and may not be effective for all individuals.
The unpredictability of the effectiveness of such therapy is a key reason why many people consider alternative treatments.
Health Canada’s Stance on Psilocybin as a Therapeutic Choice
Over the past two decades, preliminary clinical trials have highlighted the potential advantages of psychedelic substances for treating complex mental disorders. Specifically, Psilocybin has been found to quickly and lastingly relieve existential distress in patients nearing the end of their lives.
Recognizing the potential efficacy of these proposed hallucinogenic mushrooms, especially when conventional treatments do not suffice, Health Canada revised the Special Access Program in 2022. This revision permits healthcare providers to request controlled substances for their patients.
Canadian Support for Psilocybin Access
A research paper published in the Palliative Care Journal evaluates societal views on psilocybin-assisted therapy for end-of-life care. The data from the study includes:
| Methodology | Data was collected from 2,800 Canadians from Québec, Ontario, Alberta, and British Columbia. 19% of these participants had previous experience with psilocybin (15% in Québec, 26% in British Columbia). |
| Findings | 79.3% view psilocybin-assisted therapy as a legitimate medical option for treating end-of-life existential distress. 63.3% believe that psilocybin should be incorporated into medical treatment. 84.8% support the public health system providing this therapy. 44.2% think that healthcare professionals should administer the substance without oversight from Health Canada. |
The findings align with surveys conducted in Canada, England, and Australia. The researchers highlighted that their study is distinctive in its focus on the use of psychoactive substances to address existential distress in end-of-life situations.
Why Canadians Support the Use of Psilocybin
An increasing number of Canadians are accepting the use of psilocybin for therapy, largely driven by evidence from esteemed research institutions. The perceived safety of psilocybin mushrooms for easing existential distress is another key factor. Subjects across various studies have not reported severe adverse health effects, such as multiple organ failure.
| Study | Approach | Outcomes |
| Johns Hopkins Study | 51 patients received a high dose of psilocybin and a low dose as an active placebo control | Immediate and prolonged |
| New York University Study | A group of 29 patients were selectively given either psilocybin or niacin, an active placebo. | The results of the study echoed those of the Johns Hopkins research. Subjects who had been administered psilocybin reported a significant psychological upliftment and a renewed viewpoint on life and death. |
| BMC Palliative Care | The study involved interviewing 19 participants, consisting of 7 doctors, 4 practicing nurses, 4 chaplains, 3 social workers, and a psychologist. It aimed to understand the perception of palliative care professionals towards existential distress and their opinion on psychedelic therapy as a possible treatment. | Palliative care professionals have indicated that psychedelic-assisted therapy (PAT) could be a promising solution for addressing existential distress. |
Patient Encounters
Scientific research isn’t the sole provider of evidence supporting the positive effects of psilocybin. Numerous patient stories highlight its potential to improve mental health and overall quality of life.
Yokoi’s Experience
Mio Yokoi, a patient with terminal stage 4 pancreatic cancer, shares her transformative journey during her assisted therapy. In her vision, she finds herself on a raft, surrounded by nature and fantastical creatures, instilling in her a deep recognition of the universe’s interconnectivity and support, bringing her immense tranquility and assurance.
Despite seeking conventional mental health services, Yokoi’s anxiety and distress persisted post her diagnosis. Psilocybin therapy enabled her to reconnect with her body while providing a tangible sense of love and support. This significantly improved her emotional and mental wellbeing.
Chrissy’s Narrative
Chrissy, a woman in her 50s, was diagnosed with stage 4 breast cancer that had metastasized to her lungs. At the time of the study, she was working full time as an administrative supervisor in healthcare and identified as an atheist. She was diagnosed with Generalized Anxiety Disorder during her screening.
Chrissy reported significant reductions in her anxiety, depression, fear of death, hopelessness, and demoralization levels. When asked about any shifts in her religious or spiritual beliefs post therapy, she indicated that the experiences had brought a sense of purpose and reality to her beliefs.
Brenda’s Journey
Brenda, a woman in her sixth decade of life, was diagnosed with stage I colon cancer. She had never taken hallucinogens, which was revealed during her screening, and she was found to meet the criteria for Chronic Adjustment Disorder, accompanied by anxiety.
Brenda experienced two near-death experiences during her therapy sessions. She came out of these sessions without any fear of death, considering it a natural part of life. She credited the study for starting her healing journey from childhood trauma. This significant transformation was reflected in her data.
Her anxiety and fear of death had decreased, while her spirituality had increased.
Availability of Magic Mushroom Products in Canada
Psilocybin capsules and other products designed to manage existential distress or other mental health conditions might not be readily available. However, reliable online dispensaries can be a practical source for these products when needed.
| Feature | Brazilian Psilocybe Cubensis | Cambodian Psilocybe Cubensis | Melmac Psilocybe Cubensis |
| Origin | Native to Brazil and some surrounding South American countries. | Located in Cambodia, near the Angkor Wat Temple. | Associated with Penis Envy mushrooms, which became popular in the 1970s. |
| Potency | Moderately potent; suitable for beginners. | Moderately potent as well; perfect for novices. | Highly potent; advised for those with moderate to high experience. |
| Effects | Causes a mental buzz, slight disorientation, enhanced color perception, euphoria, spiritual experiences, increased creativity, and better focus. | Triggers an energizing and enduring high, minor visual changes, increased creativity, euphoria, a gentle physical high, fractal images, and feelings of joy. | Leads to profound shamanic experiences, vision quests, intense mystical experiences, increased creativity, focus, social awareness, and mood improvement. |
Ease End-of-life Discomfort with Psilocybin Products
End-of-life or existential distress can heavily burden many patients as they near the end of their lives. Traditional treatments may not always effectively alleviate this distress, prompting a rise in the Canadian advocacy for easier access to magic mushrooms in public healthcare. This increasing public interest could
We advocate for regulatory authorities to recognize the therapeutic potential of magic mushrooms. Obtain your psychedelics and mushroom delivery from Buy Shrooms Canada.
Frequently Asked Questions
What should patients expect when participating in Psilocybin-Assisted Therapy?
Experiences with Psychedelic-assisted therapy (PAT) vary significantly between individuals. To ensure a positive outcome, it is crucial to prepare appropriately and follow the recommended steps. A thorough evaluation and mental readiness are necessary before patients can consume the substance.
- Prior to the Session: A complete assessment is conducted for patients. The therapist discusses the patient’s goals and expectations to set the course for the session. An explanation of the process’s impact and what to expect during the session is provided to the patient.
- The Session: Patients receive a regulated dose of the substance in a serene, distraction-free environment to promote relaxation and self-reflection. The therapist offers constant support and guidance during this time.
- After the Session – Integration Therapy: This therapy helps patients interpret and digest their experiences. Successive sessions provide ongoing support and counselling to reinforce the insights and personal growth attained during therapy.
How does psilocybin affect the brains of distressed patients?
Psilocybin interacts with the brain by attaching to serotonin receptors, notably the 5-HT2A receptor. This interaction can cause alterations in perception, mood, and cognitive function, leading to profound changes in consciousness, emotional breakthroughs, and novel viewpoints.
Is psilocybin therapy available to everyone?
Psilocybin therapy is not appropriate for everyone. Patients suffering from specific mental health conditions or existential distress are thoroughly screened to exclude those with a history of psychosis.
Related Reading:
